Fibrates and statins are associated with a 42-fold and 8-fold increased risk of myopathy, respectively, compared to normal controls, but the incidence remains low, at 6 per 100,000 and 1 per 100,000, respectively.
Considerable concern exists among clinicians regarding the risk-benefit ratio of long-term anticoagulation compared to antiplatelet treatment. In order to compare the risk of vascular events and bleeding complications in patients with AF, van Walraven and associates analyzed data from 6 randomized clinical trials.
Three recent studies have provided epidemiologic data that increased intake of antioxidants may be associated with a reduced risk of developing AD.
In this thoughtful, well-balanced review, Clarke and Guttman review the evidence for using new dopamine agonists to treat patients with early PD.
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.
